Envista Q1 2026: Dental Tech's Top Earnings Performer

Envista Holdings led the dental technology sector in Q1 2026, posting 14.4% revenue growth and a 50% jump in adjusted EPS — outpacing every major peer in the healthcare equipment space.

Envista Q1 2026 revenue of $706 million exceeded consensus by $25 million, with 9.5% core sales growth across all major business units.
Adjusted EPS of $0.36 beat estimates by 14.9%, with adjusted diluted EPS up 50% year-over-year.
Envista authorized an incremental $300 million share repurchase program and reaffirmed its full-year 2026 guidance.

What Happened

Envista Holdings (NYSE: NVST) reported first-quarter 2026 revenue of $705.5 million, up 14.4% from the same period a year earlier, surpassing the Wall Street consensus of $680.5 million. Core sales growth — which strips out currency effects and portfolio changes — came in at 9.5%.

Adjusted diluted earnings per share of $0.36 topped the $0.31 analyst estimate by 14.9% and represented a 50% increase from the prior-year quarter. The result marked the fourth consecutive quarter in which all of Envista's major business units delivered positive growth, extending a turnaround that began to gain traction through 2025.

Revenue growth in the quarter was broad-based. The Specialty Products & Technologies segment — which houses orthodontic and implant businesses — recorded 8.4% core growth. The Equipment and Consumables segment delivered 11.5% core growth, driven by diagnostic imaging and practice-consumable product lines. Spark clear aligners remained a primary growth engine, particularly in North America and Western Europe, where pricing gains contributed meaningfully to top-line expansion.

Chief Executive Paul Keel attributed the results to intensified customer engagement and the commercialization of a series of recently launched products, signaling that the company's investment cycle is beginning to convert into measurable revenue.

Market Reaction

Despite the earnings beat, NVST stock fell 7.25% in after-hours trading following the May 6 release, closing at $24.29 against a prior-session close of $26.19. The drawdown reflected broad investor caution over the pace of guidance upgrades rather than disappointment with the print itself. Over the preceding 52 weeks, the stock had traded between $18.77 and $30.42, and had rallied 37.1% on a trailing 12-month basis ahead of the report.

Analyst sentiment remained constructive. Evercore ISI raised its price target to $33 from $30, maintaining an Outperform rating, while William Blair upgraded Envista to Outperform, citing evidence of durable execution on the company's multi-year turnaround. Of 11 analysts covering NVST, six carry Buy ratings and five Hold, with no Sell recommendations.

Peer Comparison

Among dental technology and healthcare equipment stocks, Envista's Q1 revenue growth stood as the strongest in the peer group. Align Technology (ALGN) reported $1.04 billion in revenue, up 6.2% year-over-year, beating estimates by 1.8%. Henry Schein (HSIC) posted $3.44 billion in revenue, up 7.7%, exceeding consensus by 2.8%. Dentsply Sirona (XRAY) reported $880 million, roughly flat year-on-year, though it beat analyst expectations by 4.8% on improved cost discipline.

Across the dental equipment category, companies collectively surpassed Wall Street revenue forecasts by an average of three percentage points in Q1 2026, supported by long-running adoption of digital dentistry tools, AI-enabled diagnostics, and 3D printing. Envista's 14.4% reported growth and 14.9% EPS beat led the group on both metrics.

Strategic Context

The Q1 result reinforced the credibility of Envista's ongoing operational transformation. Full-year 2025 delivered 6.5% core revenue growth and 26% adjusted EBITDA growth, and the Q4 2025 print — $751 million in sales, up 15% year-on-year, with non-GAAP EPS of $0.38 beating consensus by 17.7% — established the trajectory that Q1 2026 extended.

Management's decision to authorize a $300 million incremental buyback alongside reaffirmed guidance signals confidence in free cash flow generation and balance-sheet capacity. The company is simultaneously increasing R&D and sales-and-marketing spending at double-digit rates, a capital allocation posture consistent with companies investing through a product cycle rather than managing for near-term margin extraction.

Outlook

Envista reaffirmed its 2026 full-year guidance, with consensus projecting revenue of $2.86 billion — growth of roughly 5.2% — and adjusted EPS of $1.42, up 19.3% year-over-year. Q2 2026 results are scheduled for release on August 5, 2026.

The underlying dental technology market is expected to expand from $8.31 billion in 2026 toward $11.48 billion by 2031 at a 5.5% compound annual growth rate, providing a durable volume backdrop. With Spark gaining share in the clear aligner category and the Equipment and Consumables segment accelerating, Envista enters the second half of 2026 with the sector's strongest recent growth record.

Earnings }}